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ABSTRACT
Introduction: A study has been developed to assess
the use and effectiveness of budesonide MMX for
mild-to-moderate active ulcerative colitis (UC) in
routine clinical practice.
Methods and analysis: A prospective, multicentre,
observational, cohort study of 300 patients prescribed
budesonide MMX for the treatment of mild-to-
moderate active UC will be conducted in Europe, Israel
and Canada. Patients will be treated with budesonide
MMX9 mg daily for induction of remission for
≤8 weeks. Data on effectiveness, including patient-
reported outcomes, tolerability and use will be
recorded at the end of treatment and at ≥2 weeks after.
The primary outcome (improvement ≥3 point in the
clinical subscores of the UC Disease Activity Index
score at the end of treatment) will be compared in:
patients who receive budesonide MMX added to
mesalazine >2 weeks after increased/optimised
mesalazine dose for the treatment of flare (late add-
on); patients who receive budesonide MMX added to
mesalazine ≤2 weeks since mesalazine increased/
optimised for the treatment of flare, or without
mesalazine dose modification (early add-on); and
patients who receive budesonide MMX as monotherapy
for the treatment of flare (mono). Propensity scoring
will be used to minimise bias and confounding
inherent in observational studies.
Ethics and dissemination: First ethical approval:
Ethikkommission der Ärztekammer Hamburg (12/22/
2015). The results will be published in full.
Discussion: Completion of primary data collection is
expected in December 2017. Our results will provide
further evidence on the effectiveness of budesonide
MMX to support clinicians in their daily practice and
inform therapeutic guidelines.
Trial registration number: NCT02586259.
INTRODUCTION
Ulcerative colitis (UC) is a chronic, inﬂam-
matory disease of the colon and rectum,
characterised by intermittent ﬂares, with
diarrhoea, rectal bleeding, urgency and ten-
esmus, alternating with periods of remis-
sion.1 UC affects over two million people in
Europe,2 presenting a signiﬁcant burden to
society, healthcare resources and expend-
iture.3 The symptoms of the disease can have
a major impact on patients’ quality of life
(QoL), affecting their personal life, perform-
ance at work and ability to enjoy leisure activ-
ities.4 5 Patients with mild-to-moderate
disease can normally be managed in an out-
patient setting and do not require hospital-
isation. The European Crohn’s and Colitis
Organisation (ECCO) guidelines recom-
mend that left-sided or extensive
mild-to-moderate active UC should initially
be treated with an aminosalicylate enema
1 g/day combined with oral mesalazine
(5-aminosalicylic acid; 5-ASA) >2 g/day.6
Systemic corticosteroids, such as prednisol-
one, are effective for inducing rapid remis-
sion in active UC, but the side effects of
systemic corticosteroids in particular, limit
their short-term and long-term use so they
are usually reserved for patients with symp-
toms of active UC whose disease does not
respond to mesalazine.6 7 The most frequent
side effects include mood changes, sleep dis-
turbances, acne, insomnia, moon face, ﬂuid
retention, hirsutism, ﬂushing and striae,
while the most severe include diabetes,
hypertension, osteoporosis, cataracts, and
hypothalamopituitary-adrenal suppression.8 9
The systemic side effects associated with
conventional corticosteroids has led to the
development of a corticosteroid with less sys-
temic effects. Budesonide is a synthetic glu-
cocorticosteroid, structurally related to
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prednisolone, but with 15 times greater afﬁnity for the
glucocorticoid receptor as well as higher topical activ-
ity.10 11 Budesonide has a low systemic bioavailability
(around 10%) due to a high ﬁrst-pass effect in the liver,
therefore, systemic effects with budesonide are signiﬁ-
cantly less than with conventional corticosteroids.11 At
doses clinically equivalent to systemically acting glucocor-
ticosteroids, budesonide gives signiﬁcantly less
hypothalamic-pituitary-adrenal axis suppression and
steroid-associated side effects compared with prednisol-
one.12 There are three formulations of budesonide cur-
rently available. The two standard formulations
(Budenofalk gastroresistant capsules; Dr Falk Pharma
GmbH, Germany,13 and Entocort CR capsules,
AstraZeneca, UK,14) are both designed to release the
drug only at the distal ileum and proximal colon,13 14
and are therefore not optimal for the treatment of UC.
A third formulation, budesonide MMX (Cortiment,
Ferring Pharmaceuticals Ltd), is the ﬁrst glucocorticos-
teroid designed for topical release to the whole colon
using a multimatrix system (MMX);15 thus, overcoming
the limited release of other budesonide formulations for
treating UC, especially in the left-sided location. MMX
extended-release technology is characterised by a multi-
matrix structure covered by a gastroresistant coating that
dissolves in intestinal ﬂuids having a pH >7.16
Budesonide MMX is indicated in adults for induction of
remission in patients with mild-to-moderate active UC,
where mesalazine treatment is not sufﬁcient.16 The
recommended daily dose for induction of remission is
one 9 mg tablet in the morning, for up to 8 weeks.16
The rationale behind treatment with budesonide
MMX is to maximise anti-inﬂammatory activity while
minimising systemic side effects. Two pivotal phase III
studies, CORE (Colonic Release Budesonide) I and II,
were conducted to evaluate the efﬁcacy, tolerability and
safety of budesonide MMX9 mg as monotherapy
(without concomitant treatment with mesalazine) for
inducing remission in mild-to-moderate UC.17 18 The
primary efﬁcacy end point in both studies was combined
clinical and endoscopic remission at Week 8, deﬁned as
UC Disease Activity Index (UCDAI) score ≤1 with a
score of 0 for rectal bleeding and stool frequency, no
mucosal friability on colonoscopy, and a ≥1-point reduc-
tion in endoscopic index score from baseline. Secondary
end points were clinical improvement, deﬁned as a
≥3-point improvement in the UCDAI score from base-
line to Week 8, and endoscopic improvement, deﬁned
as a ≥1-point reduction in the endoscopy subscore of
the UCDAI from baseline to Week 8.17 18 The results
were consistent across the two studies, and in a pooled
analysis of data from both studies, the combined clinical
and endoscopic remission rates were signiﬁcantly greater
than placebo (6.2%) for the budesonide MMX9 mg
group (17.7%; p=0.0002).19 Compared with placebo,
budesonide MMX9 mg also improved the rates of
symptom resolution (26.3% vs 14.3%; p=0.0015) and
mucosal healing (27.6% vs 17.1; p=0.0092%).19
A further phase IIIb study (CONTRIBUTE) compared
budesonide MMX with placebo as add-on therapy to
oral mesalazine monotherapy in patients with UC.20 In
this phase IIIb clinical study, patients inadequately con-
trolled after at least 6 weeks of mesalazine ≥2.4 g/day
were randomised to add once-daily budesonide
MMX9 mg or placebo to their existing mesalazine treat-
ment for 8 weeks. The primary and secondary efﬁcacy
end points were similar to those used in the CORE
studies.17 18 20 A greater percentage of budesonide
MMX-treated patients than placebo-treated patients
achieved a score of 0 (20% vs 12.3%, p=0.0248), indica-
tive of endoscopic remission. Budesonide MMX also
induced histological healing in a greater percentage of
patients than placebo (27% vs 17.5%, p=0.0155).20 In a
pooled analysis of safety data from ﬁve clinical studies,
budesonide MMX administered for up to 8 weeks
demonstrated a favourable safety and tolerability proﬁle
for the induction of remission in patients with
mild-to-moderate active UC.21 Budesonide MMX9 mg
was associated with normal mean cortisol concentrations
at ﬁnal visit and an adverse event (AE) incidence com-
parable with placebo.21
Budesonide MMX has been demonstrated in rando-
mised controlled trials (RCTs) to be efﬁcacious therapy
for mild-to-moderate active UC and is associated with
few adverse effects.17–19 How the efﬁcacy of inﬂamma-
tory bowel disease (IBD) therapies in RCTs translates
into effectiveness in clinical practice is of crucial import-
ance, since it is recognised that patients included in
RCTs are not representative of a real-life IBD setting,
and parameters at baseline may be different compared
with those for patients in real life.22 23 Where budeso-
nide MMX ﬁts in the UC treatment paradigm—as start-
ing therapy or after oral mesalazine has failed—also
requires further deﬁnition. Furthermore, in the case of
add-on therapy, at what stage should budesonide MMX
be given? The current ECCO guidelines recommend
waiting for 6 weeks before stepping up to corticosteroids,
although ECCO recognises that it is common practice in
many European centres to introduce oral steroids at an
early stage due to the speed of response they offer.6
Based on data from the CORE studies,17 18 and given its
favourable safety proﬁle over systemic steroids,21 it has
been suggested that budesonide MMX should be consid-
ered as the ﬁrst-choice corticosteroid in patients not
adequately controlled with mesalazine.24 In future treat-
ment algorithms for UC, budesonide MMX would be
ideally situated when mesalazine therapy is not sufﬁcient
and before systemic steroids.24
More real-world, population-based data, including
patient-reported outcomes (PROs), on the clinical
effectiveness of budesonide MMX would help to fully
deﬁne its role in UC. A PRO is ‘any report of the status
of a patient’s health condition that comes directly from
the patient, without interpretation of the patient’s
response by a clinician or anyone else’.25 The Food and
Drug Administration (FDA) is moving towards PROs as
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an important aspect of assessing disease activity of
IBD.26 PROs are collected via standardised question-
naires designed to measure an explicit concept (con-
struct) such as symptoms, functioning (activity
limitations), health status, health-related QoL (HRQoL)
or QoL.27 A study has therefore been developed to
assess the use of budesonide MMX in routine clinical
practice. With the results, we intend to validate a new
treatment algorithm for gastroenterologists that deﬁnes
the place in therapy of budesonide MMX, and, thereby,
to improve the management of UC and the QoL of
patients suffering from this chronic disease.
METHODS AND ANALYSIS
Study objectives
The primary objective is to assess the effectiveness of
budesonide MMX. Secondary objectives are to assess the
tolerability of budesonide MMX in a real-life setting and
to determine how budesonide MMX is prescribed and
used by gastroenterologists in routine clinical practice
(as monotherapy or add-on therapy to mesalazine, and
the timeframe for add-on therapy).
Study design
This is a prospective, multicentre, multinational, obser-
vational, cohort study, which does not require any
changes in the current clinical management of patients
with UC by the treating clinician (ﬁgure 1). The
ClinicalTrials.gov identiﬁer is NCT02586259.
Participating centres
It is anticipated that 50–100 centres in Europe, Israel
and Canada will enrol patients, primarily from gastro-
enterology outpatient departments.
Study population
Patients from different countries will be enrolled by gas-
troenterologists based in clinics, hospitals and specia-
lised centres. Patients can be included if they meet all
the following inclusion criteria:
1. are aged ≥18 years;
2. are seen in the outpatient department;
3. have been prescribed budesonide MMX for the treat-
ment of mild-to-moderate active UC;
4. have received adequate information regarding this
non-interventional study and are able to understand
and voluntarily sign the Informed Consent form.
Patients will be excluded if they meet any of the follow-
ing criteria:
1. have severe active/fulminant UC;
2. are being treated with antibiotics or corticosteroids
for the current ﬂare;
3. have had a total/subtotal colectomy;
4. are hypersensitive to the active substance, lecithin
(derived soya oil, peanut oil) or to any of the
excipients;
5. are enrolled and involved in an interventional study;
6. are considered inappropriate by the investigators to
participate in the study.
Study outline
Eligible patients will be recruited at the outpatient
department of each participating centre. Patient enrol-
ment will be agreed after the treatment decision is
made. Patients will be treated according to routine clin-
ical practice and budesonide MMX will be prescribed in
accordance with the terms of the country marketing
authorisation. The recommended dose of budesonide
MMX for induction of remission is one 9 mg tablet daily
in the morning, for up to 8 weeks.16 The clinician will
decide if and how the dose should be reduced, and the
duration of the tapering-off period, if required. These
data will be collected throughout the tapering-off period
until treatment has been discontinued or after a
6-month tapering-off period (whichever occurs earlier).
Data collection and monitoring
Eligible patients will be seen at the outpatient depart-
ment of each participating centre at baseline (Day 1), at
the end of induction treatment (daily), and at follow-up
≥2 weeks after the end of the last treatment dose
(table 1). On Day 1, data, as recommended by current
ECCO guidelines,2 will be collected by the investigator
or from the patient’s medical record. Patients will be
given the option to ﬁll in the questionnaires (SIBDQ,
WPAI) on Day 1 and at the end of the induction treat-
ment (daily) visit (SIBDQ, WPAI, treatment satisfaction
scale), approximately 4–8 weeks after the investigator
has decided to treat the patient with budesonide MMX
to induce remission. An electronic case report form
(eCRF) will be used to capture data. During these con-
tacts, the clinician will also evaluate the information
reported in the patient’s weekly diary (if any), and will
capture the data on the appropriate eCRF.
At the end of induction treatment (daily), the clin-
ician will capture the following data: symptoms and
severity of ﬂare; AEs reported by patients (event name,
seriousness, start date, stop date, causality and
outcome); status of budesonide MMX treatment, and
status of other treatments (mesalazine, other corticoster-
oids, immunosuppressive drug or biologics, and
non-UC-related concomitant treatments). Depending on
routine clinical practice at the participating centre, the
clinician will also perform a faecal calprotectin test and
evaluate the patient’s UCDAI endoscopic subscore. Two
weeks after the end of the last treatment dose (or up to
a maximum of 6 months for a prolonged tapering-off
period), the clinician will assess ﬂare activity and any
switch to other drugs, (eg, corticosteroids, immunosup-
pressive drug or biologics (type of therapy, start date,
dose and regimen)) if any, and any AEs reported by the
patient (event, seriousness, start date, stop date, causality
and outcome). At the time of completion of follow-up
or early discontinuation, the date will be recorded. In
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the case of early discontinuation, the reason for discon-
tinuation will also be recorded.
Effectiveness end points
Primary effectiveness end point. The primary effectiveness
end point will be the clinical beneﬁt seen in a real-life
setting, deﬁned as the percentage of patients with clin-
ical improvement ≥3 points in the UCDAI clinical sub-
score (stool frequency, rectal bleeding, Physician’s
Global Assessment) at the end of treatment.
Secondary effectiveness end points. Secondary effectiveness
end points will be the percentage of patients with clin-
ical remission, deﬁned as a UCDAI clinical subscore ≤1
at the end of treatment; the percentage of patients with
symptom resolution (rectal bleeding=0+stool frequency
≤1) at the end of treatment, and the percentage of
patients with full symptom resolution (rectal bleeding=0
+stool frequency=0) at the end of treatment. PROs will
be used as secondary end points and will include time
to symptom resolution (rectal bleeding, stool frequency,
urgency); change in QoL, assessed using the Short
Inﬂammatory Bowel Disease Quality of Life (SIBDQ)
questionnaire at the end of treatment;28 change in
health economic parameters, assessed using the Work
Productivity and Activity Impairment (WPAI) at the end
of treatment;29 30 and treatment satisfaction evaluation
at the end of treatment, assessed using an analogue
scale where 0=totally unsatisﬁed and 10=very satisﬁed.31
Faecal calprotectin, as well as endoscopies, will be tested
at the beginning and end of treatment at the discretion
of the individual clinician. In the subpopulation in
which a faecal calprotectin test is performed, the per-
centage of patients with faecal calprotectin within
normal range at the end of treatment will be assessed.
In the subpopulation in which endoscopies are per-
formed at the beginning and end of treatment, the per-
centage of patients with endoscopic healing (UCDAI
endoscopic subscore=0) and the percentage of patients
in remission (UCDAI endoscopic subscore ≤1) at the
end of treatment will be assessed.
Tolerability end point
The secondary end point will be the tolerability of bude-
sonide MMX in a real-life setting. Safety assessments will
include AE and adverse drug reaction reporting. All AEs
will be coded according to the Medical Dictionary for
Regulatory Activities.
Statistical analysis
Sample size was calculated on the percentage of patients
with clinical improvement ≥3 points in the clinical sub-
scores of UCDAI score at the end of the induction treat-
ment (once daily budesonide MMX9 mg tablet). A
sample size of 300 evaluable patients will allow estima-
tion of the two-sided 95% CI with a width equal to
11.0% of the clinical beneﬁt when the expected percent-
age is equal to 38% based on the Phase III trials data.
The Clopper-Pearson’s formula was used for the
computation.
Descriptive analyses will be carried out using the tools
available within standard spreadsheet and database
packages. Continuous variables will be summarised
using the number of patients, mean, SD, minimum, ﬁrst
quartile, median, third quartile and maximum. For cat-
egorical variables, data will be summarised by the
number and percentage of patients in each category.
Incidence percentages will be calculated. When summar-
ising categorical variables, if there are any missing
responses, these will be shown as a separate category.
When summarising continuous variables, the number of
non-missing observations will be displayed. All withdra-
wals after enrolment will be summarised by time of, and
reason for, discontinuation.
Statistical analyses will be performed using the SAS
System V.9.4. A two-tailed p<0.05 will be considered stat-
istically signiﬁcant. Analyses will be presented with 95%
CIs. Association between the response and clinical vari-
ables (with variables with a p<0.20 in univariate analysis)
will also be tested using logistic regression analysis. Odds
ratios with 95% CIs will be derived from the logistic
model. To evaluate effectiveness, the primary outcome
(improvement ≥3 point in the clinical subscores of the
UCDAI score at the end of treatment) will be compared
in patients who will receive budesonide MMX added to
mesalazine at least 14 days (>2 weeks) after increased/
optimised mesalazine dose for the treatment of ﬂare
(late add-on) (Cohort 1) (ﬁgure 2); patients who will
receive budesonide MMX added to mesalazine within
Figure 1 Study design flow
chart design: prospective,
observational, cohort study. This
study does not require any
changes in the standard clinical
management of patients with UC
by the treating clinician. MMX,
multimatrix; UC, ulcerative colitis.
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14 days (≤2 weeks) since mesalazine increased/opti-
mised for the treatment of ﬂare, or without mesalazine
dose modiﬁcation (early add-on) (Cohort 2) (ﬁgure 2);
and patients who will receive budesonide MMX as
monotherapy for the treatment of ﬂare (mono) (Cohort
3) (ﬁgure 3). Matching will be based on the propensity
score method, which attempts to balance the treatment
groups so as to reduce bias of treatment selection.32 33
The propensity score estimates the probability, using
logistic regression, of receiving a particular treatment
conditioned on the individual’s baseline characteristics.
The rationale behind propensity scores is to allow design
and analysis of an observational (non-randomised) study
so that it mimics particular characteristics of a RCT.
ETHICS AND DISSEMINATION
Ethics
The study will be conducted in accordance with the
principles of the Declaration of Helsinki and ‘good clin-
ical practice’ guidelines. The protocol has been
approved by an independent ethics committee. The ﬁrst
ethics committee approval was: Approval Number: 12/
22/2015; Board Name: Ethikkommission der
Ärztekammer Hamburg. The regulatory permission to
perform the study will be obtained in accordance with
applicable national regulatory requirements. All ethical
and regulatory approvals for the particular country will
be available before the study is initiated. Consent from
all patients will also be obtained from the participating
centres. Patients prescribed budesonide MMX for the
treatment of mild-to-moderate active UC will be coun-
selled, and written informed consent will be obtained
from all patients if the inclusion criteria are met. For
patients not qualiﬁed to give their legal consent, written
informed consent will be obtained from the guardian, in
accordance with national/local regulations. If such
patients can understand the risks and beneﬁts of the
study, they will also be informed, and will provide their
written consent.
Patient safety
AEs will be reported as per the national safety reporting
requirements of each participating country. Depending
on national regulations, all non-serious AEs or only
budesonide MMX-related non-serious AEs, spontan-
eously notiﬁed by the patients or observed/recorded by
the investigator during the whole study period (from
the signature of the informed consent until the end of
the study) will be recorded by the investigator in a spe-
ciﬁc AE page of the eCRF. All serious AEs will be
recorded regardless of relationship with the medicinal
product. The investigator will be responsible for ensur-
ing that any AE recorded in the eCRF (either observed
by the investigator or reported by the patient) will also
be recorded in the patient’s medical record. All AEs will
be reported to ethics committees, National Health
Authority and investigators, depending on the national
requirement of each country participating in the study.
Dissemination plan
At the end of the study, one or more manuscripts on the
full results would be published in peer-reviewed journal(s).
Data from individual countries may also be published sep-
arately. All study data will be stored on a fully validated,
eCRF system held by an independent third-party contract
Table 1 Data collection
Visit 1 2 3
Time
Day
1*
End of
induction
treatment
(daily)*
≥2 weeks
after end of
last
treatment
dose
Informed consent† x
Inclusion/exclusion
criteria
x
Demographics x
Concomitant
diseases
x
UC history x
Current flare
activity
x x
Concomitant
treatments
x x x
Effectiveness
assessments
(UCDAI clinical
subscore)
x x
WPAI
questionnaire‡
x x
SIBDQ
questionnaire‡
x x
Treatment
satisfaction scale
x
Tolerability x x
Patient weekly
diary§
x x
Fecal calprotectin¶ x x
UCDAI endoscopy
subscore¶
x x
*Visits will be made in accordance with routine clinical practice,
and budesonide MMX treatment must be prescribed in the usual
manner in accordance with the terms of the marketing
authorisation of each participating country.
†Written informed consent must be obtained prior to any
study-related data collection.
‡Depending on country regulations for non-interventional study
and on local clinical practice.
§The investigator will also offer the patient a weekly diary. If she/
he wishes to complete this, the diary will be provided at inclusion,
and the patient will be requested to return the diary to the
physician at the end of daily treatment visit, whenever this occurs.
The diary will be completed with information related to the last
3 days of the week.
¶Optional: to be collected, if available, because it is considered by
the clinician as routine clinical practice.
SIBDQ, Short Inflammatory Bowel Disease Quality of Life; UC,
ulcerative colitis; UCDAI, UC Disease Activity Index; WPAI, Work
Productivity and Activity Impairment.
Danese S, Hart A, Dignass A, et al. BMJ Open Gastro 2016;3:e000092. doi:10.1136/bmjgast-2016-000092 5
Open Access
research organisation. The investigator will approve/
authorise the eCRF entries for each patient. A data man-
agement plan will be created before data collection begins,
and will describe all functions, processes and speciﬁcations
for data collection, cleaning and validation. After the study
database is declared clean and is released to the statistician,
a ﬁnal copy of the database will be stored at the sponsor.
DISCUSSION
UC is a chronic, idiopathic, inﬂammatory disorder,
which has a signiﬁcant impact on every aspect of the
affected individual’s life, and accounts for substantial
costs to healthcare systems and society.2 Corticosteroids
are part of the armamentarium for induction of remis-
sion in UC and although they may improve symptoms,
they have signiﬁcant adverse effects.7 Budesonide MMX
is a new option for treating mild-to-moderate active UC,
providing gastroenterologists with an orally administered
alternative to systemic corticosteroids. In RCTs, budeso-
nide MMX was effective, with an AE proﬁle comparable
with placebo.19 Most patients with UC included in RCTs,
however, are not representative of a real-life UC
setting,22 which raises questions about the clinical
beneﬁt of this treatment in clinical practice. The goal of
our study is to understand real-life efﬁcacy of budeso-
nide MMX for inducing remission in mild-to-moderate
UC, and to determine how it is prescribed and used by
gastroenterologists in routine clinical practice. Whereas
efﬁcacy measures how well a treatment works in clinical
trials or laboratory studies, treatment effectiveness
relates to how well it works in clinical practice.34 One of
the challenges, however, when conducting effectiveness
studies, is to distinguish real treatment effects from
those caused by bias or confounding. We will address
this potential bias by matching patients in the different
treatment groups based on a propensity score, a vali-
dated method,23 32 33 and by doing so, we aim to
provide valuable information on the therapeutic effects
of budesonide MMX in clinical practice. The propensity
scoring methodology has been used successfully in a
retrospective study of antitumour necrosis factor-α use in
paediatric Crohn’s disease.35 As far as we are aware,
however, our study represents the ﬁrst prospective, obser-
vational study to measure the clinical effectiveness of an
IBD therapy in routine clinical practice using propensity
scoring. We anticipate that the innovative methodology
of our study will help to inform the design of future real-
world studies assessing the effectiveness of IBD
therapies.
Patients’ involvement in the care they receive is being
given greater emphasis, and as a result, PRO measures
are becoming increasingly important end points for clin-
ical effectiveness studies.26 This is particularly the case
for products developed to treat chronic, disabling condi-
tions, such as UC, where the intention is not to cure but
to induce remission, ameliorate symptoms, facilitate
functioning and, ultimately, to improve QoL.26 PROs
can evaluate symptoms, signs, functional status, percep-
tions, or other aspects, such as tolerability, from the
patient’s perspective, and complement clinician-
reported measures.36 In our study, PRO data will be
Figure 2 Cohorts 1 and 2:
add-on therapy primary outcome:
improvement ≥3 point in the
clinical subscores of Ulcerative
Colitis Disease Activity Index
score at the end of treatment.
MMX, multimatrix.
Figure 3 Cohort 3: monotherapy
primary outcome: improvement
≥3 point in the clinical subscores
of the Ulcerative Colitis Disease
Activity Index score at the end of
treatment. MMX, multimatrix.
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collected via the SIBDQ, WPAI and treatment satisfac-
tion scale questionnaires, as well as from the patient’s
weekly diary. To address the potential bias due to PROs,
patient weekly diaries and questionnaires will be com-
pleted by the patient alone, without any involvement of
the investigator. The information provided is in line with
current thinking from the FDA on the importance of
PROs in assessing disease activity in IBD25 26 and will
help inform clinical care and decision-making.
The results of our study are expected to provide infor-
mation in the ﬁeld of UC and further evidence on
effectiveness to support clinicians in their daily practice
and inform therapeutic guidelines.
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